Cresset Asset Management’s Charles River Laboratories CRL Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $839K | Sell |
5,530
-121
| -2% | -$18.4K | ﹤0.01% | 835 |
|
|
2025
Q1 | $851K | Buy |
5,651
+24
| +0.4% | +$3.61K | ﹤0.01% | 831 |
|
|
2024
Q4 | $1.04M | Sell |
5,627
-1,127
| -17% | -$208K | 0.01% | 765 |
|
|
2024
Q3 | $1.33M | Buy |
6,754
+811
| +14% | +$160K | 0.01% | 1000 |
|
|
2024
Q2 | $1.23M | Sell |
5,943
-105
| -2% | -$21.7K | 0.01% | 932 |
|
|
2024
Q1 | $1.64M | Sell |
6,048
-26
| -0.4% | -$7.05K | 0.01% | 733 |
|
|
2023
Q4 | $1.44M | Sell |
6,074
-876
| -13% | -$207K | 0.01% | 720 |
|
|
2023
Q3 | $1.36M | Buy |
6,950
+2,558
| +58% | +$501K | 0.01% | 668 |
|
|
2023
Q2 | $923K | Buy |
+4,392
| New | +$923K | ﹤0.01% | 850 |
|
|
2022
Q1 | – | Sell |
-666
| Closed | -$250K | – | 1019 |
|
|
2021
Q4 | $250K | Buy |
666
+1
| +0.2% | +$375 | ﹤0.01% | 955 |
|
|
2021
Q3 | $274K | Buy |
665
+124
| +23% | +$51.1K | ﹤0.01% | 894 |
|
|
2021
Q2 | $200K | Buy |
+541
| New | +$200K | ﹤0.01% | 956 |
|
|
2019
Q2 | – | Sell |
-324
| Closed | -$47K | – | 727 |
|
|
2019
Q1 | $47K | Buy |
324
+157
| +94% | +$22.8K | ﹤0.01% | 803 |
|
|
2018
Q4 | $19K | Buy |
+167
| New | +$19K | ﹤0.01% | 715 |
|